Navigation Links
Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
Date:1/26/2011

WOBURN, Mass., Jan. 26, 2011 /PRNewswire/ -- Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay. The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring less than five minutes for sample preparation. Multiplex protein assays can be helpful in evaluating the association between elevated protein levels, patient phenotype and drug response.

The Angio Qx Immunoassay is a member of the Avantra QPDx™ biomarker detection product line for use with the Q400 Biomarker Workstation.  This platform consists of a completely self-contained immunoassay BioChip and instrument, for use in the automated measurement of key biomarkers.  

Avantra is currently working with leading experts and institutions on the development of additional biomarker panels directed at specific diseases with an emphasis in the field of oncology for research use only (RUO).  Avantra intends to seek regulatory approval for its assay technologies in the future.

The power and simplicity of Avantra's QPDx platform offers users a rapid, easy-to-use, high quality bench top quantitative multiplex protein assay platform with extremely low CVs and very little setup time.

"The initial shipment of Avantra's QPDx biomarker product line represents the first milestone in Avantra's strategy to develop a suite of oncology focused multiplex biomarker panels.  We see a tremendous opportunity for our QPDx product line and we are excited about the work we are doing with our partners to commercialize additional oncology specific biomarker panels," says Brian McKernan, CEO of Avantra.

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis.  Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

www.AvantraBio.com

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.


'/>"/>
SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
2. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
3. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
4. Ambit Biosciences Initiates Two Phase I Clinical Trials
5. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
6. Cell Biosciences Announces US Patent Issuance
7. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
8. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
9. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
11. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):